Navigation Links
Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
Date:3/14/2012

In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction.

This potential new drug target belongs to a class of receptors called the nicotinic acetylcholine receptors (nAChRs). One subtype of nAChRs, called alpha4beta2 is a well-known target for nicotine's addictive effects and the therapeutic effect of the smoking cessation drug varenicline. SRI researchers are now studying another, lesser-known subtype, called alpha3beta4 nAChR, which has recently shown to play a role in the addictive properties of cocaine, morphine, and nicotine.

Using AT-1001, a highly selective alpha3beta4 compound developed by Astraea Therapeutics, SRI researchers found that addiction processes could be disrupted. In preliminary studies, AT-1001 also reduced nicotine withdrawal symptoms such as anxiety.

Because addictive drugs act on the brain's "reward circuit," many people compulsively take them despite their harmful consequences. Feelings of pleasure are caused by the release of brain chemicals, or neurotransmitters, and their increased activity in the brain reward circuit. The key neurotransmitter in the reward circuit is dopamine, which produces changes in addictive behavior. Researchers speculate that disruption of the alpha3beta4 nAChR system using highly selective drugs such as AT-1001 may interrupt this reward circuitry.

"Currently, there are no therapeutics approved to treat addiction to stimulants such as cocaine, so it is intriguing to find a promising drug receptor target and to see that AT-1001 can indeed affect phenomena that are thought to be deeply tied to the addictive nature of cocaine and other drugs of abuse," said Taline Khroyan, Ph.D., Senior Behavioral Pharmacologist in SRI's Center for Health Sciences.

Findings from these collaborative studies were recently presented at the Society for Neuroscience Annual Meeting in a study titled "AT-1001, a Highly Selective alpha3beta4 nicotinic Receptor Antagonist is Effective in Blocking Place Preference, Behavioral Sensitization, and Withdrawal Effects of Various Drugs of Abuse." The presentation was highlighted by the Society for describing the innovative approach taken by the research team.


'/>"/>

Contact: Dina Basin
dina.basin@sri.com
650-859-3845
SRI International
Source:Eurekalert

Related biology news :

1. New mouse collaborative cross resource promises new cures and treatments for diseases
2. Collaborative Health Consortium Announces eCollaboration Forum Final Agenda for HIMSS 2012
3. Collaborative effort uncovers DNA duplications that may be responsible for genomic-based diseases
4. DFG to fund 8 new collaborative research centers
5. BGI announces collaborative research agreements with Oregon State University
6. UCSB awarded $15 million by Dow to establish collaborative institute for materials research and education
7. Louisiana State University leads collaborative effort to identify genes supporting life in extreme conditions
8. Danforth Center Collaborative Research Program receives funding to improve crop yield in Africa
9. UNC-Duke ties lead to collaborative finding about cell division & metabolism
10. The first studies utilizing the Collaborative Cross mice are published in Genome Research
11. Mouse virus erroneously linked to chronic fatigue syndrome, UCSF collaborative study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... FALLS CHURCH, Va. (PRWEB) , ... July 08, ... ... , The Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, ... product may need a comparability study, but what is the most effective way ...
(Date:7/2/2020)... (PRWEB) , ... July 01, 2020 , ... ... presented its phase 1a findings of Neihulizumab, a biologic for the treatment of ... June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... and solutions for glioblastoma—the most common and aggressive adult brain cancer—announced today the ... PhD. Senior Fellows are charged with supporting the organization’s initiatives and overall vision. ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... June 29, 2020 , ... ... competitively procured purchasing contracts to its membership, recently named BioFit Engineered Products ... with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and carts ...
(Date:6/28/2020)... JOSE, Calif. (PRWEB) , ... June 25, 2020 ... ... globe, researchers are racing to develop a vaccine or drug treatment. In an ... Recursion has publicly released the world’s largest imaging dataset portraying therapeutic ...
(Date:6/23/2020)... ... 23, 2020 , ... Kerafast Inc. , developers of ... the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, ... SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) ...
(Date:6/23/2020)... ... 22, 2020 , ... Dracen Pharmaceuticals Inc., announced today that ... during the American Association for Cancer Research Virtual meeting. One poster describes the ... single agent activity in KEAP1 mutant tumor models of NSCLC. , ...
Breaking Biology Technology: